ReviewWorld journal of hepatology2017
Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma.
Review in World journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 94 citations in OpenAlex.
- Pictorial review of abdominopelvic diseases with elevated alpha-fetoprotein levels.Abdominal radiology (New York) · 2026Review
- MRI features and LI-RADS categorization of combined hepatocellular-cholangiocarcinoma: a scoping review with prognostic implications.La Radiologia medica · 2026Article
- Viral vs. Non-Viral Combined Hepatocellular-Cholangiocarcinoma: Distinct Genomic Landscapes and Survival Outcomes.Journal of gastrointestinal cancer · 2026Article
- Update on the clinical features, treatment and histogenesis of combined hepatocellular-cholangiocarcinoma.Oncology letters · 2026Article
- Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma: A Retrospective Registry-Based Study Using the Korean Organ Transplant Registry (KOTRY).Annals of transplantation · 2025Article
- Radiologic and Pathologic Insights in Combined Hepatocellular-Cholangiocarcinoma: A Report of Three Cases.Reports (MDPI) · 2025Article
- Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?Hepatology international · 2025Article
- MRI features of combined hepatocellular-cholangiocarcinoma.Abdominal radiology (New York) · 2025Review
- Combined hepatocellular carcinoma-cholangiocarcinoma with sarcomatoid features: new insights into a rare and aggressive tumor.Journal of gastrointestinal oncology · 2024Article
- Article
- How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?Abdominal radiology (New York) · 2024Article
- Sarcomatoid change in combined hepatocellular carcinoma and cholangiocarcinoma as a poor prognostic factor.Journal of gastrointestinal oncology · 2024Article
- Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.Journal of clinical and translational hepatology · 2024Review
- Current advances and future directions in combined hepatocellular and cholangiocarcinoma.Gastroenterology report · 2024Review
- Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor-associated macrophages.Cancer reports (Hoboken, N.J.) · 2023Article
- Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.Abdominal radiology (New York) · 2023Review
- The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.International journal of molecular sciences · 2023Review
- [Advances in imaging diagnosis of mixed-type liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Review
- Review
- Association between air pollution and primary liver cancer in European and east Asian populations: a Mendelian randomization study.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.